Gemtuzumab ozogamicin is a drug-linked monoclonal antibody (an antibody-drug conjugate) that was used to treat acute myeloid leukemia from 2000 to 2010.

The global Gemtuzumab Ozogamicin Drugs market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Gemtuzumab Ozogamicin Drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall Gemtuzumab Ozogamicin Drugs market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Gemtuzumab Ozogamicin Drugs in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Gemtuzumab Ozogamicin Drugs manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Pfizer 
...

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
5mg/Vial
4.5mg/Vial

Segment by Application
Hospital
Pharmacy